Pfizer faces criticism for COVID-related social media posts, casting doubt on vaccine safety
-
Pfizer criticized for COVID social media posts damaging pharmaceutical industry reputation • 0:03
-
Comparison made to past incidents like Credit Suisse in Switzerland • 0:21
-
Discussion on potential long-term effects of vaccines and past vaccine-related issues • 1:53
-
Challenges faced by those questioning vaccine safety and risks • 2:02
-
Medium and long-term effects of vaccines highlighted with past example of narcolepsy • 2:27
-
Article links Pfizer’s actions to discredit on pharmaceutical industry • 3:00
Regulatory breaches and misleading claims by Pfizer regarding COVID-19 vaccine promotion
-
Pfizer breached regulatory code five times, including misleading claims and promoting unlicensed medicines • 3:28
-
Complaint raised about misleading COVID-19 vaccine promotion on social media by Pfizer employees • 4:11
-
Public misunderstanding of relative risk reduction vs. absolute risk reduction in vaccine efficacy • 5:13
-
Promotion of vaccine as 95% effective without clarifying relative risk reduction • 6:04
-
Immediate reporting of misinformation by vigilant individual regarding Pfizer’s claims • 6:37
-
Pharmaceutical industry’s silence on Pfizer’s misleading promotion despite industry awareness • 7:00
Pfizer faces repercussions for breaching social media guidelines, risking industry reputation
-
Credit Suisse found guilty of money laundering charges in Switzerland Criminal Court • 7:08
-
Damages credibility of Swiss banking sector, drawing industry into disrepute • 7:30
-
PMCA provides social media guidance for pharmaceutical companies • 8:19
-
Fisa reprimanded multiple times for misleading statements about vaccines • 9:57
Investigation into Pfizer's misleading marketing tactics resulted in a minimal financial penalty compared to massive profits from COVID vaccines
-
Pfizer faced multiple cases related to misleading claims on social media platforms • 10:34
-
European parliamentary question raised concerns about the taxation of Pfizer’s $30 billion profits from COVID vaccines • 11:22
-
The delay in the ruling on Pfizer’s case raises questions about the legal tactics employed by the company • 12:10
-
Comparisons with previous complaints against other companies show a longer timeframe for resolution in Pfizer’s case • 13:02
Lack of accountability in pharmaceutical industry despite financial gains and public health concerns
-
Industry’s silence on vaccine benefits and risks in November 2020 • 14:28
-
Questioning the ethics of prioritizing profit over public interest • 15:04
-
Damage to public trust in pharmaceutical industry due to COVID vaccine campaign • 15:49
-
Concerns about the long road to rebuilding public trust • 16:01